Observations and Commentary on Medicine and Current Events
I wrote this essay for the HealthCareBlog amid the COVID-19 pandemic. As everyone started discussing re-opening the country and the economy, I reflected back to the 1918 flu pandemic and told the story of the city of Philadelphia. I will always argue that we need to learn from history to determine our present and future. … Read more
I wrote this article for the HealthCareBlog amid COVID-19 pandemic. I looked back at the ZIKA story by reading a book that discussed the topic; I attempted to contrast between ZIKA and COVID to identify lessons we should have learned from prior epidemics and pandemics.
I originally wrote this article for the HealthCareBlog amid the COVID-19 pandemic. I was growing tired of how people are using the term “Essential Oncology”, which implies the presence of non-essential oncology. I reflected on the importance to view oncology through the lenses of the most important stakeholders – our patients. COVID-19 is for sure challenging our thinking and behaviors, but we need to always keep patient needs and are front and center in how we proceed.
This is part 2 of an article where was interviewed for at Bio Similar Development. The article was discussing biosimilars and their impact on patients, oncologists, and healthcare system. This is critical as we are experiencing changes in reimbursement models and operational challenges for effective healthcare delivery.
As we kicked off 2020, one of the most anticipated events for the industry was the introduction of several more Herceptin, Avastin, and Rituxan competitors in the curative oncology mAb space. After the first three launches which will be completed in March, the U.S. will have finally welcomed a little more than half of the 26 biosimilars currently approved.
I read this fascinating book “Chasing my Cure” written by the amazing David Fajgenbaum on his journey fighting Castleman Disease. Battling this disease has shaped David’s journey and forming the Castleman Disease Collaborative Network (CDCN). I then interviewed David on my “Outspoken Oncology” Podcast.
Mark Lewis and I reflected on ASCO-19 and how all stakeholders were involved. It was truly fun to write this piece for the ASCO-Post.
Interviewing Dr. DeVita was a dream coming true; I interviewed him for my podcast and wrote a book review for the HealthCareBlog on his “The Death of Cancer” book. Dr. DeVita is a pioneer of lymphoma and is an icon for every oncologist, so having him on my podcast was an honor I will never forget.